Kevin Kunzmann

Data presented this weekend at the 3rd Congress of the European Academy of Neurology will show its varied efficacy in MS progression prevention.

The treatment was tested in a trial of 7,513 patients hospitalized and susceptible to the condition.

Stephen Krieger, MD, explains how the monoclonal antibody changed the state of MS treatment.

The subcutaneous treatment can be used for HAE attacks at home.

Navigating the adverse effects, and potential benefits, for the neurological condition's treatments.

The Republican Senate repeal to the Affordable Care Act came 2 months after the House passed the American Health Care Act.

The anti-CGRP monoclonal antibody showed long-term efficacy versus placebo in migraine pain impact.

The CANVAS results yield promise against cardiovascular events, but a risk of amputations.

William Polonsky, PhD, CDE, explains where more benefits lie in T2D patients using the monitoring devices.

The mixed amphetaminies salts formulation included 16 clinical trials results in its application.

The once-daily treatment is an oral formulation of central nervous system stimulant methylphenidate.

Bipolar disorder patients with Alzheimer's have a 2.3-fold increased chance of having been diagnosed with HCV.

TALICIA will undergo a confirmatory Phase III trial.

The FDA accepted an abbreviated new drug application for Sandoz ANDA.

The in vivo microscopy has been used in other peripheral neuropathies.

This comes a week after its first request for a drug removal.

The oral treatment fares better than most in Parkinson's dyskinesia.

Samuel Frank, MD, director of the Huntington's Disease Society America Centers of Excellence at the Beth Israel Deaconness Medical Center, discusses hitting the moving target of Huntington's treatment, and his research on deutetrabenazine for the rare disease.

Minocycline can reduce risk of conversion over 6 months of treatment.

A disease that affects the motor and cognitive system can be treated well by physical therapy and exercise, Daniel M. Corcos, PhD, said.

The monoclonal antibody will seek FDA approval this year.

Daniel M. Corcos, PhD, discusses the value of routine balance intervention activities for Parkinson's disease patients at the 21st International Congress of Parkinson's Disease and Movement Disorders.

Aleksandar Videnovic, MD, associate professor at the Massachusetts General Hospital, discusses new patient monitoring opportunities and other methods of treatment for one of Parkinson's disease patients' most common symptoms.

BMS-986168 significantly reduces CSF free eTau.

A Phase II-B trial with early to moderate PD patients showed efficacy.

Anthony Lang, MD, FRCPC, professor and director of the Division of Neurology at the University of Toronto, discusses the potentially comprehensive care of investigational disease modifying treatment PRX002,

The study gauged elderly Parkinson's patients over a 5-year span.

Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

Norika Malhado-Chang, MD, assistant professor of Neurology at University of California at Davis, discusses how progress in Parkinson's disease and movement disorders is changing the scope of comprehensive care, addressing non-motor symptoms, and supplying tools for the next generation of neurology specialists.